November 26th Shanghai Healthcare Drinks Event

View Calendar
2019-11-26 6:30 pm - 9:00 pm

November 26th Shanghai Healthcare Drinks Event

Hear the latest on the Biotech environment in Europe, the latest on Vaccine technologies in Europe and China, and details about the Tasly-Transgene JV.

Click here to RSVP
Deep Dive into European-China Biotech Cooperation
WHEN
Tuesday, November 26th 6:30 to 9:00 p.m.
Free Admission - Chinese and English
Phone: Clare - 18616316925
WHERE
Shanghai – WPP Building – 6 Floor
399 Hengfeng Road, Jingan District
Metro Station: Hanzhong Road

On Tuesday, November 26th from 6:30 p.m. to 9:00 p.m., Shanghai Healthcare Drinks Alliance, Kantar Health, Bryan Garnier and ChinaMed Capital will hold an after work fireside chat with Philippe Archinard, CEO of Transgene and Robin Zhang, VP of Business Development for Tasly. The fireside chat will be moderated by Donald Gao, President of BioFront Drug Discovery Center. 

The fireside chat will delve into various topics including:

  1. The current situation in Europe’s Life Science industry and the general view on Chinese innovation and capital.
  2. Lessons from both sides of the Transgene-Tasly historic Joint Venture 
  3. Review of vaccine development in China and updates on new technologies including cancer vaccines with an eye to how China can lead.
  4. Debate on if its time for Chinese biotech companies to focus on Europe instead of the US or somewhere else.
     


 

Philippe Archinard
Chairman and CEO, Transgene

Philippe Archinard became Chief Executive Officer (CEO) in December 2004 and Chairman in June 2010. Prior to joining Transgene, Philippe served as CEO of Innogenetics. He began his professional career with bioMérieux in 1985, where he held various positions in France and the United States, including CEO of U.S. operations. Since 2014, Philippe Archinard has been Chairman of the Bioaster Scientific Cooperation Foundation, an Institute of Technological Research dedicated to infectiology and microbiology. He holds a chemical engineering degree and a PhD in biochemistry from Lyon University.

 


 

Robin Zhang 
Executive Director, VP of Strategy and BD, Tasly Biopharmaceuticals

Since he joined Tasly, Dr. Zhang successfully closed more than 20 deals with about 200 million USD investment. Prior joined Tasly, Dr. Zhang served several positions in Pfizer, Bayer, IMS, Alfred Mann Foundation, and UBS. Dr. Zhang graduated from Beijing Medical University and received his PhD of Pathology from School of Medicine & Dentistry and MBA of Health Science Management and Finance from Simon Business School of University of Rochester. 

 


 

Donald Gao 
Co-Founder and President, BioFront Innovation Accelerator

Mr. Donald Gao is Co-Founder and President of BioFront Innovation Accelerator. Previously, he was the Founding Partner of Marathon Venture Partners and worked at several international private equity funds. Earlier, Donald conducted early stage investments in life science and biotechnology in Silicon Valley and was engaged in cross-border leverage financing in Citigroup. Donald received an MBA from Harvard Business School. He is also the President of HBS Club of Shanghai.

Click to Register
Copyright © 2019 Healthcare Drinks, All rights reserved.
Want to change how you receive these emails?
You can update your preferences or unsubscribe.
 
www.healthcaredrinks.com